Orbit Discovery

Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals.   Under the terms of the agreement, Orbit will deploy […]

Companies Evergreen Discovery and Orbit Discovery have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers activities including designing peptide libraries, hit identification and hit validation to confirm cell surface binding properties. The radiopharmaceuticals market is rapidly expanding with the development of a variety […]

A new collaboration aims to accelerate development of advanced G-protein coupled receptor (GPCR)-targeting therapeutics for cachexia caused by cancer and other chronic conditions.  Orbit Discovery has entered a partnership with Endevica Bio following the release of data proving that the company’s lead compound is safe and well-tolerated in Phase I trials.  Endevica’s technology platform allows […]

Orbit Discovery and start-up SanegeneBio have entered into a Master Service Agreement to identify tissue-specific delivery of a wide range of RNA therapeutics.  The agreement covers activities ranging from hit ID to cell-based internalisation studies, with an option for Sanegene to further develop the hits resulting from the screening activities.  Orbit’s technology enables the screening […]